N6-methyladenosine

''N''⁶-Methyladenosine (m⁶A) was originally identified and partially characterised in the 1970s, and is an abundant modification in mRNA and DNA. It is found within some viruses, and most eukaryotes including mammals, insects, plants and yeast. It is also found in tRNA, rRNA, and small nuclear RNA (snRNA) as well as several long non-coding RNA, such as '' Xist''.

The methylation of adenosine is directed by a large m⁶A methyltransferase complex containing METTL3, which is the subunit that binds ''S''-adenosyl-L-methionine (SAM). ''In vitro'', this methyltransferase complex preferentially methylates RNA oligonucleotides containing GGACU and a similar preference was identified ''in vivo'' in mapped m⁶A sites in Rous sarcoma virus genomic RNA and in bovine prolactin mRNA. More recent studies have characterized other key components of the m⁶A methyltransferase complex in mammals, including METTL14, Wilms tumor 1 associated protein ( WTAP), VIRMA and METTL5. Following a 2010 speculation of m⁶A in mRNA being dynamic and reversible, the discovery of the first m⁶A demethylase, fat mass and obesity-associated protein ( FTO) in 2011 confirmed this hypothesis and revitalized the interests in the study of m⁶A. A second m⁶A demethylase alkB homolog 5 (ALKBH5) was later discovered as well.

The biological functions of m⁶A are mediated through a group of RNA binding proteins that specifically recognize the methylated adenosine on RNA. These binding proteins are named m⁶A readers. The YT521-B homology (YTH) domain family of proteins ( YTHDF1, YTHDF2, YTHDF3 and YTHDC1) have been characterized as direct m⁶A readers and have a conserved m⁶A-binding pocket. Insulin-like growth factor-2 mRNA-binding proteins 1, 2, and 3 (IGF2BP1–3) are reported as a novel class of m⁶A readers. IGF2BPs use K homology (KH) domains to selectively recognize m6A-containing RNAs and promote their translation and stability. These m⁶A readers, together with m⁶A methyltransferases (writers) and demethylases (erasers), establish a complex mechanism of m⁶A regulation in which writers and erasers determine the distributions of m⁶A on RNA, whereas readers mediate m⁶A-dependent functions. m⁶A has also been shown to mediate a structural switch termed m⁶A switch.

The specificity of m⁶A installation on mRNA is controlled by exon architecture and exon junction complexes. Exon junction complexes suppress m⁶A methylation near exon-exon junctions by packaging nearby RNA and protecting it from methylation by the m⁶A methyltransferase complex. m⁶A regions in long internal and terminal exons, away from exon-exon junctions and exon junction complexes, escape suppression and can be methylated by the methyltransferase complex.

Species distribution

Yeast

In budding yeast (''Saccharomyces cerevisiae''), the expression of the homologue of METTL3, IME4, is induced in diploid cells in response to nitrogen and fermentable carbon source starvation and is required for mRNA methylation and the initiation of correct meiosis and sporulation. mRNAs of IME1 and IME2, key early regulators of meiosis, are known to be targets for methylation, as are transcripts of IME4 itself.

Plants

In plants, the majority of the m⁶A is found within 150 nucleotides before the start of the poly(A) tail.

Mutations of MTA, the ''Arabidopsis thaliana'' homologue of METTL3, results in embryo arrest at the globular stage. A >90% reduction of m⁶A levels in mature plants leads to dramatically altered growth patterns and floral homeotic abnormalities.

Mammals

Mapping of m⁶A in human and mouse RNA has identified over 18,000 m⁶A sites in the transcripts of more than 7,000 human genes with a consensus sequence of /A/UG>A]m⁶AC >A/Cref name="Meyer_2012"/> consistent with the previously identified motif. The localization of individual m⁶A sites in many mRNAs is highly similar between human and mouse, and transcriptome-wide analysis reveals that m⁶A is found in regions of high evolutionary conservation. m⁶A is found within long internal exons and is preferentially enriched within 3' UTRs and around stop codons. m⁶A within 3' UTRs is also associated with the presence of microRNA binding sites; roughly 2/3 of the mRNAs which contain an m⁶A site within their 3' UTR also have at least one microRNA binding site. By integrating all m⁶A sequencing data, a novel database called RMBase has identified and provided ~200,000 sites in the human and mouse genomes corresponding to N6-Methyladenosines (m⁶A) in RNA.

Precise m6A mapping by m6A-CLIP/IP (briefly m6A- CLIP) revealed that a majority of m6A locates in the last exon of mRNAs in multiple tissues/cultured cells of mouse and human, and the m6A enrichment around stop codons is a coincidence that many stop codons locate round the start of last exons where m6A is truly enriched. The major presence of m6A in last exon (>=70%) allows the potential for 3'UTR regulation, including alternative polyadenylation. The study combining m6A-CLIP with rigorous cell fractionation biochemistry reveals that m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover.

m⁶A is susceptible to dynamic regulation both throughout development and in response to cellular stimuli. Analysis of m⁶A in mouse brain RNA reveals that m⁶A levels are low during embryonic development and increase dramatically by adulthood. In mESCs and during mouse development, FTO has been shown to mediated LINE1 RNA m⁶A demethylation and consequently affect local chromatin state and nearby gene transcription. Additionally, silencing the m⁶A methyltransferase significantly affects gene expression and alternative RNA splicing patterns, resulting in modulation of the p53 (also known as TP53) signalling pathway and apoptosis.

m⁶A is also found on the RNA components of R-loops in human and plant cells, where it is involved in regulation of stability of RNA:DNA hybrids. It has been reported to modulate R-loop levels with different outcomes (R-loop resolution and stabilization).

The importance of m⁶A methylation for physiological processes was recently demonstrated. Inhibition of m⁶A methylation via pharmacological inhibition of cellular methylations or more specifically by siRNA-mediated silencing of the m⁶A methylase ''Mettl3'' led to the elongation of the circadian period. In contrast, overexpression of ''Mettl3'' led to a shorter period. The mammalian circadian clock, composed of a transcription feedback loop tightly regulated to oscillate with a period of about 24 hours, is therefore extremely sensitive to perturbations in m⁶A-dependent RNA processing, likely due to the presence of m⁶A sites within clock gene transcripts. The effects of global methylation inhibition on the circadian period in mouse cells can be prevented by ectopic expression of an enzyme from the bacterial methyl metabolism. Mouse cells expressing this bacterial protein were resistant to pharmacological inhibition of methyl metabolism, showing no decrease in mRNA m⁶A methylation or protein methylation.

Clinical significance

Considering the versatile functions of m⁶A in various physiological processes, it is thus not surprising to find links between m⁶A and numerous human diseases; many originated from mutations or single nucleotide polymorphisms (SNPs) of cognate factors of m⁶A. The linkages between m⁶A and numerous cancer types have been indicated in reports that include stomach cancer, prostate cancer, breast cancer, pancreatic cancer, kidney cancer, mesothelioma, sarcoma, and leukaemia. The impacts of m⁶A on cancer cell proliferation might be much more profound with more data emerging. The depletion of METTL3 is known to cause apoptosis of cancer cells and reduce invasiveness of cancer cells, while the activation of ALKBH5 by hypoxia was shown to cause cancer stem cell enrichment. m⁶A has also been indicated in the regulation of energy homeostasis and obesity, as FTO is a key regulatory gene for energy metabolism and obesity. SNPs of ''FTO'' have been shown to associate with body mass index in human populations and occurrence of obesity and diabetes. The influence of FTO on pre-adipocyte differentiation has been suggested. The connection between m⁶A and neuronal disorders has also been studied. For instance, neurodegenerative diseases may be affected by m⁶A as the cognate dopamine signalling was shown to be dependent on FTO and correct m⁶A methylation on key signalling transcripts. The mutations in HNRNPA2B1, a potential reader of m⁶A, have been known to cause neurodegeneration. The IGF2BP1–3, a novel class of m⁶A reader, has oncogenic functions. IGF2BP1–3 knockdown or knockout decreased MYC protein expression, cell proliferation and colony formation in human cancer cell lines. The ZC3H13, a member of the m6A methyltransferase complex, markedly inhibited colorectal cancer cells growth when knocked down.

Additionally, m⁶A has been reported to impact viral infections. Many RNA viruses including SV40, adenovirus, herpes virus, Rous sarcoma virus, and influenza virus have been known to contain internal m⁶A methylation on virus genomic RNA. Several more recent studies have revealed that m⁶A regulators govern the efficiency of infection, replication, translation and transport of RNA viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Zika virus (ZIKV). These results suggest m⁶A and its cognate factors play crucial roles in regulating virus life cycles and host-viral interactions.

Aside from affecting viruses themselves, m⁶A modifications can also disrupt the innate immune response. For example, in HBV, m⁶A modifications were shown to disrupt the recognition of viruses by RIG-1, a pattern recognition receptor in the immune system. Modifications can also disrupt downstream signaling pathways via mechanisms including ubiquitination and changes in the levels of protein expression.

In bacteria

M6A methylation is also widespread in bacteria, influencing functions such as DNA replication, repair, and gene expression, and prokaryotic defense.

In replication, M6A modifications mark DNA regions where the initiation stage takes place as well as regulates precise timing via the Dam methyltransferase in E. coli. Another enzyme, Dam DNA methylase regulates mismatch repair using M6A modifications which influence other repair proteins by recognizing specific mismatches.

In some cases of DNA protection, M6A methylations (along with M4C modifications) play a role in the protection of bacterial DNA by influencing certain endonucleases via the restriction-modification system, decreasing the influence of bacteriophages. One such role is introducing a methyltransferase which recognizes the same target site that restriction enzymes (Type 1 restriction enzymes) attack and modifying it in order to stop such enzymes from attacking bacteria DNA.

In Development

m⁶A modifications, along with other epigenetic changes, have been shown to play important roles during eukaryotic development. Hematopoietic Stem Cells (HSCs), Neuronal Stem Cells (NSCs) and Primordial Germ Cells (PCGs) have all been shown to undergo m⁶A modifications during growth and differentiation. Depending on the stage of development, modifications to HSCs can either promote or inhibit stem cell differentiation by affecting the epithelial-to-hemopoietic transition via METTL3 inhibition or depletion. m⁶A modifications to NSCs can causes changes in brain size, neuron formation, long-term memory, and learning ability. These changes are often caused by inhibition of either METTL or YTHDF readers and writers. In the reproductive system, m⁶A modifications have been shown to disrupt the maternal-to-zygotic mRNA transition and negatively affect both gamete formation and fertility. Similar to NSCs, inhibition of the METTL and YTHDF families of proteins is often a catalyst for these changes.

References

{{DEFAULTSORT:Methyladenosine, N6-
Nucleosides
Purines
Hydroxymethyl compounds